Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Summit Therapeu ADR
(NQ:
SMMT
)
29.48
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
8,577
Open
29.48
Bid (Size)
28.78 (1)
Ask (Size)
29.18 (1)
Prev. Close
29.48
Today's Range
29.48 - 29.48
52wk Range
1.640 - 33.89
Shares Outstanding
97,381,774
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Here's Why Everyone's Talking About Summit Therapeutics
Today 4:24 EDT
Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock.
Via
The Motley Fool
Alphabet To $200? Here Are 10 Top Analyst Forecasts For Monday
September 16, 2024
Via
Benzinga
Performance
YTD
+1016.67%
+1016.67%
1 Month
+140.65%
+140.65%
3 Month
+273.16%
+273.16%
6 Month
+616.40%
+616.40%
1 Year
+1528.73%
+1528.73%
More News
Read More
Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024
September 16, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
September 15, 2024
Via
Benzinga
Here's How Much $100 Invested In Summit Therapeutics 5 Years Ago Would Be Worth Today
September 13, 2024
Via
Benzinga
Summit Therapeutics Options Trading: A Deep Dive into Market Sentiment
September 11, 2024
Via
Benzinga
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?
September 14, 2024
Via
The Motley Fool
Why Summit Therapeutics Skyrocketed 123% This Week
September 13, 2024
Via
The Motley Fool
Why Summit Therapeutics Stock Is Soaring Again Today
September 12, 2024
Via
The Motley Fool
Signet Jewelers Posts Better-Than-Expected Earnings, Joins NETGEAR, Lovesac And Other Big Stocks Moving Higher On Thursday
September 12, 2024
Via
Benzinga
Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million Sale
September 12, 2024
Via
Investor's Business Daily
Summit Therapeutics Surges on Trial Results: Time to Buy?
September 12, 2024
Via
MarketBeat
Why Summit Therapeutics (SMMT) Stock Is Rising Today
September 12, 2024
Via
Benzinga
Summit Therapeutics Raises $235 Million
September 12, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Is Summit Therapeutics a Buy Now?
September 10, 2024
Via
The Motley Fool
Why Summit Therapeutics Rocketed Over 60% Today
September 09, 2024
Via
The Motley Fool
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
September 09, 2024
Via
Benzinga
Starbucks To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Monday
September 09, 2024
Via
Benzinga
Biotech Stocks: Lung Cancer Treatment Outflanks Merck's Keytruda
September 09, 2024
Via
Investor's Business Daily
Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half
September 09, 2024
Via
Benzinga
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
September 09, 2024
Via
Benzinga
Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China
September 08, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 06, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024
August 12, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.